KLS:7081

Pharmaniaga Berhad · KLS · Healthcare · MYR · FY for 2025

Figures on this page computed 2026-11-08 13:04 UTC

Last close

n/aMYR

Market data

11.3xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
MYR
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
1.2%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
-1.2%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
MYR
- computed

Safety is the furthest below its sector's middle: 0.31 against 0.53 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.07x

-0.88x

0.63x

0.83x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales1.07x
Its own average over 6 years, 3.69B.
Profit-0.88x
Its own average over 6 years, -55.0M.
Free cash flow0.63x
Its own average over 6 years, -75.1M.
Debt0.83x
Its own average over 6 years, 983.3M.
Pricen/a
Its own average over 0 years. Market data

Profit is furthest from its own average, at -0.88 times.

Sales is 1.07 times its own 6-year average; Profit is -0.88 times its own 6-year average; Free cash flow is 0.63 times its own 6-year average; Debt is 0.83 times its own 6-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 6-year average1.07
Source
computed
Statement
income
Fiscal year
2025
Reported in
MYR
Profit against its own 6-year average-0.88
Source
computed
Statement
income
Fiscal year
2025
Reported in
MYR
Free cash flow against its own 6-year average0.63
Source
computed
Statement
income
Fiscal year
2025
Reported in
MYR
Debt against its own 6-year average0.83
Source
computed
Statement
income
Fiscal year
2025
Reported in
MYR
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
MYR